Research Article

Citrus aurantium Naringenin Prevents Osteosarcoma Progression and Recurrence in the Patients Who Underwent Osteosarcoma Surgery by Improving Antioxidant Capability

Table 2

Baseline characters of osteosarcoma patients.

Naringenin group ()Control group () values

Age, years23.6 ± 12.724.3 ± 12.10.21
Gender, male/female27/2029/190.77
Smoking, n (%)19 (40.4)21 (43.8)0.74
Alcoholic intake, n (%)17 (36.2)18 (37.5)0.89
Body mass index, kg/m225.6 ± 6.924.9 ± 7.20.14
Osteosarcoma types
 Intramedullary osteosarcoma39 (83.0)38 (79.2)0.64
 Juxtacortical osteosarcoma7 (14.9)8 (16.7)0.81
 Extraskeletal osteosarcoma1 (21.3)1 (41.7)1.00
Osteosarcoma grades
 G1, n (%)8 (17)7 (14.6)0.75
 G2, n (%)9 (19.1)10 (20.8)0.84
 G3, n (%)22 (46.8)24 (50)0.76
 G4, n (%)8 (17)7 (14.6)0.75
Osteosarcoma volume
 Before surgery248.7 ± 124.3 c.c.260.5 ± 113.7 c.c.0.13
 After surgery3.9 ± 3.9 c.c.3.5 ± 3.5 c.c.0.24
 Chemotherapy, n (%)35 (74.5)33 (68.8)0.77
 Resection length, cm13.4 ± 5.912.7 ± 6.20.25
 Stem diameter, cm11.7 ± 3.610.5 ± 4.30.16
Site
 Cancer treatment types
  Osteosarcoma surgery47 (100)48 (100)1.00
  Chemotherapy47 (100)48 (100)1.00
  Radiotherapy5 (10.6)6 (12.5)0.78
  Rehabilitation and supportive care47 (100)48 (100)1.00
  Femur, n (%)31 (66)30 (62.5)0.73
  Tibia, n (%)12 (25.5)11 (22.9)0.77
  Others, n (%)4 (8.5)7 (14.6)0.36
 Histologic type
  Osteoblastic, n (%)20 (42.6)18 (37.5)0.62
  Chondroblastic, n (%)14 (29.8)17 (35.4)0.56
  Fibroblastic, n (%)9 (19.1)8 (16.7)0.75
  Others, n (%)4 (8.5)5 (10.4)0.97
 Differentiation status
  High, n (%)31 (66)33 (68.8)0.71
 Low, n (%)16 (34)15 (31.3)0.77
  Pulmonary metastasis, n (%)4 (8.5)5 (10.4)0.97